With First Ophthalmologic Biosimilar Set to Debut, Specialist Says Close Attention Required for Unexpected Side Effects

Prof. Taiji Sakamoto, Ophthalmology Department, Kagoshima University Graduate School of Medical and Dental Sciences A biosimilar of the anti-VEGF antibody Lucentis (ranibizumab) is expected to hit the market this month as the first follow-on biologic in the Japanese ophthalmology field...read more